How gut bacteria and diet can improve immune response to melanoma
Investigating the role of the microbiota in enhancing memory T cell function during caloric restriction to promote melanoma control
This study is looking at how eating less and taking care of your gut health might help your immune system fight melanoma better, which could lead to new dietary tips for improving cancer treatment.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Weill Medical Coll of Cornell Univ NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-10818345 on NIH RePORTER |
What this research studies
This research investigates how caloric restriction and gut microbiota can enhance the function of memory T cells, which are crucial for controlling melanoma. By understanding the molecular mechanisms involved, the study aims to identify dietary interventions that could improve cancer immunotherapy outcomes. Patients may benefit from insights into how their diet and gut health can influence their immune response to cancer treatment. The research combines laboratory experiments with potential clinical applications to develop effective nutritional strategies for cancer care.
Who could benefit from this research
Good fit: Ideal candidates include melanoma patients who are interested in exploring dietary interventions as part of their treatment plan.
Not a fit: Patients with advanced melanoma who are not considering dietary changes or those with severe dietary restrictions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new dietary recommendations that enhance immune responses in cancer patients, improving treatment outcomes.
How similar studies have performed: Previous research has shown promising results in using dietary interventions to enhance immune function, suggesting potential success for this approach.
Where this research is happening
New York, United States
- Weill Medical Coll of Cornell Univ — New York, United States (Active)
Researchers
- Principal investigator: Collins, Nicholas — Weill Medical Coll of Cornell Univ
- Study coordinator: Collins, Nicholas
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.